

Drug Utilization Review Board

Meeting Minutes

Thursday, December 13, 2018
7:15 a.m. to 8:30 a.m.
Cannon Health Building
Room 125

Board Members Present:

Kumar Shah, M.Sc., P.Eng., Board Chair
Jennifer Brinton, M.D.
Eric Cannon, Pharm.D., FAMCP
Sharon Weinstein, M.D.

Kyle Kitchen, Pharm.D.
Susan Siegfried, M.D.
Katherine Smith, Pharm.D.
Aesha Drozdowski, Pharm.D.

Board Members Excused:

Neal Catalano, Pharm.D.

Dept. of Health/Div. of Health Care Financing Staff Present:

Jennifer Strohecker, PharmD, Pharmacy
Director
Joe Busby, RPh, MBA

Bryan Larson, Pharm.D.
Merelynn Berrett, R.N., PA
Heather Santacruz, R.N., PA

University of Utah Drug Regimen Review Center Staff Presenter:

Valerie Gonzales, Pharm.D.

Other Individuals Present:

Jason Bott, Lilly
Patrick Moss, Sarepta
Leslie Zanetti, Sarepta
Don Moran, Teva
Lori Howarth, Bayer
Elena Martinez Alonso, U of U
Michael Faithe, Amgen

Russell Butterfield, U of U
Lauren Heath, U of U
Deron Grothe, Teva
Dale Grant, Neurocrine
TL, U of U
Tom Burrows, Lilly
Akram Razeh, Roseman

Meeting conducted by: Kumar Shah

1. **Welcome & Housekeeping:** Kumar Shah opened the meeting and reminded everyone to sign the rosters. He also introduced Jennifer Strohecker as the interim DUR manager.
2. **Review and Approval of November Minutes:** Aesha Drozdowski made a motion to Approve the minutes from November. Susan Siegfried seconded the motion. All in favor, motion passed. Katherine Smith and Sharon Weinstein were not present for this vote.
3. **Pharmacy and Therapeutics Committee Report:** Bryan Larson reported that the committee reviewed migraine prophylaxis medications. These medications will be likely be added to the preferred drug list in January 2019. Starting in 2019, P&T Committee meetings will be held quarterly with the next meeting to be held in March 2019.

4. **Monoclonal Antibodies for Migraine Prevention:**

a. Information:

Valerie Gonzales presented peer-reviewed research and guidelines regarding the use of CGRP Antagonists for the prevention of migraines.

b. Public Comment:

1. Michael Faithe from Amgen presented information pertaining to Aimovig.
2. Don Moran from Teva presented information pertaining to Ajovy.

c. Board Discussion

1. Jennifer Strohecker asked for recommendations regarding prior authorization criteria including re-authorization criteria.
2. Eric Cannon recommended that a patient should fail at least 3 or 4 treatments prior to using a CGRP antagonist.
3. Sharon Weinstein expressed concern that primary care providers may not be adequately familiar with established guidelines for the diagnosis and treatment of migraines.
4. There was extensive discussion of headache vs migraine days in trials and guidelines with respect to the definition of chronic or episodic migraines.
5. The board also discussed what constitutes an appropriate response.

d. Board Action

1. Motion:

1. Establish a diagnosis of chronic or episodic migraines per established criteria from International Headache Society guidelines.
2. Failure after an adequate trial (at least 2 months at the maximum tolerated dose unless otherwise contraindicated) of at least one drug from each three of the following therapeutic drug categories: beta-blockers, tricyclic antidepressants, anti-epileptics, botulinum toxin A.
3. For re-authorization, a positive clinical response with improvement in headache frequency.
4. Motion to approve: Eric Cannon. Second: Sharon Weinstein. All in favor, motion passed. Kumar Shah was not present for this vote.

5. **Update on Exondys 51:**

a. Public Comment

1. Russell Butterfield was invited to address the board about Exondys 51. He made himself available to answer any questions the board had for him.

b. Board Discussion

1. The board discussed the existing prior authorization criteria and possible updates or clarifications to the existing criteria.

c. Board Action

1. **Motion:**
 1. Modify the re-authorization to require that Exondys 51 be prescribed by, or in consultation with, a neurologist experienced in the treatment of Duchenne muscular dystrophy.
 2. Motion to approve: Sharon Weinstein. Second: Eric Cannon. All in favor, motion passed. Kumar Shah was not present for this vote.
6. Jennifer provided Medicaid Pharmacy updates-
 - a. Morphine Milligram Equivalent (MME) standards will be applied to opioid prescriptions starting on 1/1/19. MME edits will be applied to opioids, in addition to existing quantity limit and day supply edits on opioids.
 1. Sharon Weinstein inquired if there was safety data to support MME levels and shared information on the Veteran Affairs Safety Study. She stressed the complexity of the high-risk opioid patient, including concurrent mental illness, etc.
 - b. DUR requirements for 2019, including opioid + benzodiazepines, opioids + antipsychotics, opioids + other dangerous combinations will be evaluated and discussed with the DUR board.
 - c. Opioid PA Criteria were presented to the Board to their review.
7. **Public Meeting Adjourned:** Eric Cannon motioned to close the meeting. Aesha Drozdowski seconded the motion. Unanimous Approval.
8. **The next meeting scheduled for** Thursday, January 10, 2019 VMAT-2 Inhibitors.

Audio recordings of DUR meetings are available online at:
<https://medicaid.utah.gov/pharmacy/drug-utilization-review-board?p=DUR%20Board%20Audio%20Recordings/>